Chison Medical Technologies Co., Ltd. (SHA:688358)
China · Delayed Price · Currency is CNY 25.61
-0.49 (-1.88%)
Oct 19, 2026, 3:00 PM CST
SHA:688358 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,872 | 3,367 | 2,738 | 4,236 | 3,857 | 3,646 | |
Market Cap Growth | -21.31% | 22.99% | -35.36% | 9.83% | 5.78% | -9.90% |
Enterprise Value | 1,845 | 2,320 | 1,674 | 3,253 | 2,837 | 2,679 |
Last Close Price | 25.61 | 29.32 | 23.01 | 34.47 | 30.91 | 28.83 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 24.65 | 28.91 | 19.49 | 28.92 | 36.44 | 32.42 |
Forward PE | 20.99 | 19.77 | 12.33 | 19.26 | - | - |
PS Ratio | 6.51 | 7.73 | 5.84 | 8.76 | 10.13 | 9.17 |
PB Ratio | 2.10 | 2.43 | 1.93 | 3.09 | 2.94 | 2.93 |
P/TBV Ratio | 2.13 | 2.47 | 1.96 | 3.14 | 2.99 | 2.98 |
P/FCF Ratio | 38.23 | 36.30 | 20.77 | 81.62 | 334.47 | 4701.59 |
P/OCF Ratio | 32.03 | 31.42 | 19.46 | 49.31 | 60.51 | 91.25 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 4.18 | 5.32 | 3.57 | 6.72 | 7.45 | 6.74 |
EV/EBITDA Ratio | 19.15 | 23.48 | 14.92 | 25.88 | 36.23 | 32.86 |
EV/EBIT Ratio | 21.82 | 26.28 | 16.66 | 28.53 | 42.84 | 37.09 |
EV/FCF Ratio | 24.56 | 25.01 | 12.70 | 62.68 | 245.99 | 3454.78 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 |
Debt / EBITDA Ratio | 0.06 | 0.03 | 0.06 | 0.08 | 0.08 | 0.02 |
Debt / FCF Ratio | 0.08 | 0.03 | 0.05 | 0.20 | 0.53 | 1.76 |
Net Debt / Equity Ratio | -0.75 | -0.77 | -0.77 | -0.74 | -0.78 | -0.82 |
Net Debt / EBITDA Ratio | -10.97 | -10.78 | -9.75 | -8.11 | -13.04 | -12.57 |
Net Debt / FCF Ratio | -13.66 | -11.47 | -8.30 | -19.63 | -88.54 | -1321.52 |
Asset Turnover | 0.27 | 0.27 | 0.30 | 0.32 | 0.26 | 0.29 |
Inventory Turnover | 1.42 | 1.43 | 1.50 | 1.25 | 1.08 | 1.95 |
Quick Ratio | 5.80 | 6.44 | 7.58 | 8.58 | 5.97 | 8.33 |
Current Ratio | 6.59 | 7.18 | 8.42 | 9.69 | 7.10 | 9.09 |
Return on Equity (ROE) | 8.43% | 8.31% | 10.07% | 10.92% | 8.27% | 9.22% |
Return on Assets (ROA) | 3.24% | 3.46% | 4.03% | 4.69% | 2.84% | 3.29% |
Return on Invested Capital (ROIC) | 20.36% | 24.77% | 26.61% | 32.05% | 23.73% | 35.60% |
Return on Capital Employed (ROCE) | 6.10% | 6.30% | 7.00% | 8.20% | 5.00% | 5.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 4.03% | 3.46% | 5.13% | 3.46% | 2.74% | 3.08% |
FCF Yield | 2.62% | 2.76% | 4.81% | 1.23% | 0.30% | 0.02% |
Dividend Yield | 4.53% | 2.93% | 4.09% | 2.12% | 2.04% | 1.10% |
Payout Ratio | 125.70% | 96.03% | 63.70% | 53.58% | 37.79% | 56.90% |
Buyback Yield / Dilution | 0.52% | -0.46% | -1.25% | 2.19% | -0.11% | -0.79% |
Total Shareholder Return | 5.05% | 2.48% | 2.84% | 4.30% | 1.92% | 0.30% |